Feature | April 01, 2013

Rox Medical Enrolls First U.K. Patients in CONTROL-HTN Hypertension Trial

April 1, 2013 — Rox Medical announced enrollment of the first U.K. patients in the CONTROL-HTN international randomized controlled trial of the Rox Flow procedure for the treatment of resistant hypertension. The first patients were enrolled at Eastbourne General Hospital, East Sussex, U.K. by doctors Neil Sulke and Stephan Furniss. For the two patients randomized to treatment, the Rox procedure was performed in the cardiac cath lab in under one hour.

"It was a very enjoyable and straightforward procedure on a patient with very difficult to control blood pressure," said Furniss. "The procedure was relatively painless and the patient showed significant improvement in blood pressure right after the procedure that we'll be anxious to monitor over the coming weeks and months. "This could be a very important new device treatment option for resistant hypertension patients," said Furniss. "We are anxious to enroll additional patients into this exciting trial."

"We like the fact that the Rox procedure is reversible and that it can treat patients who are not candidates or don't seem to respond to renal denervation," added Sulke. 

Rox Medical's Flow procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance and by diverting some arterial blood to the veins, adds lost compliance back into the vascular system. Uniquely, the Flow procedure only involves vascular structures away from vital organs like the kidneys, has an immediate effect and is fully reversible. The procedure also does not require heavy pain medications common to renal ablation techniques. The Rox procedure holds the promise of a meaningful long-term reduction in hypertension that may be combined with other device hypertension therapies.

The Rox Flow procedure for hypertension is not approved for use in the United States.

For more information: www.roxmedical.com

 

 

 

Related Content

Most Black Adults Have High Blood Pressure Before Age 55
News | Hypertension | July 30, 2018
July 30, 2018 — Approximately 75 percent of black and men women are...
American Heart Association Announces New Hypertension Center Certification
News | Hypertension | July 05, 2018
Physician practices now have access to new resources to improve their standard of quality care for hypertension...
YMCA and American Heart Association Partner to Improve Blood Pressure Control
News | Hypertension | April 05, 2018
YMCA of the USA (Y-USA) and the American Heart Association (AHA) are combining efforts to help more people better...
Higi Implementing New ACC/AHA Blood Pressure Guidelines at 11,000 North American Stations
News | Hypertension | March 28, 2018
Population health enablement company Higi announced their commitment to implement the 2017 American College of...
Petaluma Health Center Wins 2017 HIMSS Davies Award for Hypertension Control Program
News | Hypertension | February 16, 2018
February 16, 2018 — California’s Petaluma Health Center (PHC) was recently awarded a 2017 Healthcare Information and
SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension | November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension | September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension | September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
MobiusHD Device Shows Promise in Treatment of Resistant Hypertension
News | Hypertension | August 30, 2017
Vascular Dynamics Inc. announced interim results of the company’s first-in-human trial of its MobiusHD implant...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension | August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Overlay Init